Research use only · Not for human consumptionPepwizard compares vendor pricing for research-grade compounds. Nothing on this site is medical advice. How we price.
Compound sheet
Fat Loss / GIP/GLP-1/glucagon tri-agonist
07.05.2026
FAT LOSSResearch-onlyInvestigationalLow availability
Retatrutide
GIP/GLP-1/glucagon tri-agonist · 39aa · aka "LY3437943"
“Triple-agonist next-gen. Phase 3.”
No offers tracked yet.
§ 01 — Spec
Amino acids
39
Half-life
~6 days
Admin
Subcutaneous once weekly
Typical dose
Phase 2 used 1–12 mg weekly; optimal dose pending Phase 3
Live offers
0
§ 02 — Abstract
A triple agonist of GIP, GLP-1, and glucagon receptors in late-stage clinical trials, producing ~24% weight loss at 48 weeks in Phase 2 — the largest effect size of any weight-loss pharmaceutical to date.
Retatrutide simultaneously activates three incretin/metabolic receptors. The addition of glucagon agonism is thought to increase energy expenditure, complementing the appetite suppression driven by GIP and GLP-1.
Studied for
01~24% mean bodyweight reduction at 48 weeks (Phase 2)
02Additional benefits on hepatic fat content
03Potential metabolic benefits beyond weight loss
§ Codes
Live coupon for Retatrutide.
§ 03 — Stock
No approved vendor stocks Retatrutide yet.
We only feature vendors whose affiliate programmes we've signed off — no inventory padding. We're onboarding more partners and will list Retatrutide as soon as one stocks it.
Email me when it lists
We'll ping you the moment a tracked vendor lists Retatrutide.
Free · weekly
Your email. That's it. No account. No tracking pixels. Unsubscribe anytime.
§ 04 — Trend
Tracking begins.
We started tracking Retatrutide on 2026-05-07. The chart unlocks at 14 daily snapshots — currently 1 on file.
1 snapshot · floor on 07.05.2026